Xenon Pharmaceuticals’ (XENE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a research note released on Monday morning,Benzinga reports. They currently have a $53.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q1 2025 earnings at ($1.00) EPS, Q2 2025 earnings at ($1.09) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.31) EPS, FY2025 earnings at ($4.64) EPS, FY2026 earnings at ($5.74) EPS, FY2027 earnings at ($6.12) EPS, FY2028 earnings at ($5.58) EPS and FY2029 earnings at ($4.03) EPS.

Several other analysts also recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $57.38.

Xenon Pharmaceuticals Stock Up 3.9 %

Shares of NASDAQ:XENE opened at $39.10 on Monday. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -13.87 and a beta of 1.20. Xenon Pharmaceuticals has a 12 month low of $35.53 and a 12 month high of $50.99. The company’s fifty day simple moving average is $39.31 and its 200 day simple moving average is $40.33.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,492 shares of company stock worth $2,334,969. Corporate insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of XENE. Janus Henderson Group PLC increased its position in Xenon Pharmaceuticals by 144.2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after buying an additional 1,507,135 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after purchasing an additional 905,129 shares during the period. FMR LLC increased its holdings in shares of Xenon Pharmaceuticals by 8.8% in the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company’s stock valued at $294,991,000 after purchasing an additional 607,606 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at about $23,520,000. Finally, Stempoint Capital LP acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth about $14,733,000. 95.45% of the stock is owned by institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.